DHG Pharmaceutical JSCSTC:DHG -1.48%77 PB Ratio is 2.75 as of Jun. 24, 2026, which is 22% below its 10-year median of 3.51. GuruFocus rates STC:DHG with a GF Score™ of 77/100 and a GF Value™ of ₫113,344.20 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks worse than 66.49% on this metric.
DHG Pharmaceutical JSC stock PB Ratio (=2.75) is close to 10-year low of 2.57.
The historical rank and industry rank for DHG Pharmaceutical JSC's PB Ratio or its related term are showing as below:
STC:DHG'
s PB Ratio Range Over the Past 10 Years
Min: 2.57 Med: 3.51 Max: 5.78
Current: 2.75
During the past 13 years, DHG Pharmaceutical JSC's highest PB Ratio was 5.78. The lowest was 2.57. And the median was 3.51.
STC:DHG's PB Ratio is ranked worse than 66.49% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs STC:DHG: 2.75
During the past 12 months, DHG Pharmaceutical JSC's average Book Value Per Share Growth Rate was 1.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of DHG Pharmaceutical JSC was 24.90% per year. The lowest was -1.20% per year. And the median was 9.10% per year.
Back to Basics: PB Ratio
DHG Pharmaceutical JSC (STC:DHG) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's PB Ratio distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
DHG Pharmaceutical JSC (STC:DHG) has a PB Ratio of 2.75 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DHG Pharmaceutical JSC and its competitors. This is 22% below median its historical median of 3.51. Over the past decade, DHG Pharmaceutical JSC's PB Ratio has ranged from 2.57 to 5.78. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #613 out of 922 companies in the Drug Manufacturers industry, placing it in the top 66.5%.
Is DHG Pharmaceutical JSC's PB Ratio too high?
DHG Pharmaceutical JSC's current PB Ratio of 2.75 is 22% below median its 10-year median of 3.51. Over the past 10 years, this metric has ranged from a low of 2.57 to a high of 5.78. The Drug Manufacturers industry median PB Ratio is 1.88. DHG Pharmaceutical JSC's value of 2.75 is 46.3% above this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #613 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, DHG Pharmaceutical JSC has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #613 out of 922 companies for PB Ratio. This places DHG Pharmaceutical JSC in the lower half of its industry. The industry median PB Ratio is 1.88. DHG Pharmaceutical JSC's value of 2.75 is 46.3% above this benchmark. Historically, DHG Pharmaceutical JSC's own PB Ratio has ranged from 2.57 to 5.78 over the past decade. While the company's 10-year median is 3.51 vs. the industry median of 1.88, DHG Pharmaceutical JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current PB Ratio of 2.75 is 46.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current PB Ratio is 2.75, which is 22% below median its own 10-year median of 3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,344.20, compared to a current price of ₫93,300.00 — trading 17.7% below its estimated fair value. The current PB Ratio is 2.75, which is 22% below median its 10-year median of 3.51 and 46.3% above the Drug Manufacturers industry median of 1.88. DHG Pharmaceutical JSC's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current PB Ratio is 2.75 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫93,300.00 is trading 17.7% below its estimated GF Value™ of ₫113,344.20.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
PB Ratio: 2.75 (22% below median its 10-year median of 3.51)
GF Value™: ₫113,344.20 vs. price of ₫93,300.00 (17.7% below fair value)
Industry Position: 46.3% above the Drug Manufacturers median (#613 of 922)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
77GF Score
Get the complete analysis for STC:DHG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
